Ignite Creation Date:
2024-05-06 @ 1:53 PM
Last Modification Date:
2024-10-26 @ 1:21 PM
Study NCT ID:
NCT04150302
Status:
UNKNOWN
Last Update Posted:
2019-11-04
First Post:
2019-09-23
Brief Title:
Development and Validation of a Questionnaire to Measure the Impact of SBS and Its Treatments on Patients Lives
Sponsor:
Central Hospital Nancy France
Organization:
Central Hospital Nancy France
Study Overview
Official Title:
Development and Validation of a Questionnaire to Measure the Impact of Short Bowel Syndrome SBS and Its Treatments on Patients Lives
Status:
UNKNOWN
Status Verified Date:
2019-09
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ARTEMIS_GC
Brief Summary:
Today patients express a very strong need to take into account the consequences of their disease and its treatments in their therapeutic follow-up It is therefore essential to better understand the needs expectations and values of patients with SBS in order to better understand the impact of the disease on their lives and thus improve the conditions for medical social psychological and technical care The clinical expertise of health professionals and meetings with patient associations demonstrate the major gap between the parameters taken into account by physician to evaluate the evolution of the SBS and the day-to-day experience of the disease perceived by the patient
The objective of the ARTEMIS-GC study is to develop and validate an instrument to measure the impact of SBS and its treatments on daily life from the perspective of patients
The objective of the ARTEMIS-GC study is to develop and validate an instrument to measure the impact of SBS and its treatments on daily life from the perspective of patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None